The global wound care biologics market size was valued at USD 1.77 billion in 2022. It is projected to reach USD 4.10 billion by 2031, growing at a CAGR of 9.74% during the forecast period (2023–2031). Diabetes has become a worldwide epidemic, affecting both industrialized and developing nations. As the prevalence of diabetes continues to rise, a larger market for diabetes treatments is opening up. One of the most successful markets is the one for biologics used in wound care. It is expected that the increasing prevalence of diabetes will be a significant driver of the global wound care biologics market over the next few years. Diabetic ulcers affect many people with diabetes and require minor procedures and reassurance. A swath soaked in healing medication is typically applied to a patient's wound after surgery. The provision of such items by wound care biologics helps to increase the effectiveness of treatment.
Get more information on this report Download Sample Report
The growing Prevalence of Diseases & Conditions Affects Wound Healing Capabilities
Chronic and surgical wounds are physical health conditions that slow wound healing. The rising global geriatric population, the increasing incidence of traumatic wounds, the rising number of surgeries, and the rising prevalence of conditions like diabetes are all significant contributors to the dramatic uptick in chronic and surgical wounds over the past decade. Infections, ulcerations (leg or foot ulcers), and chronic wounds are all examples of wounds that can be made more common and complicated by diabetes, resulting in extensive medical care and astronomical bills. It helps the host's epithelial cells migrate and colonize the wound site by providing a preformed collagen matrix, receptors, and bound growth factors. They will increase their demand for wound care biologic products with these benefits because of the increased speed with which their wounds will heal.
High Cost of Wound Care Biologic Products
High prices for chronic wound therapies and wound care biologics may slow their uptake, particularly in price-conscious regions like Asia and the Rest of the World. Although many bioengineered products are available in these markets, physicians and patients tend to opt for traditional and essential wound care products due to their low costs, which drives up overall healthcare expenditures in the case of DFUS, a necessary application for wound care biologics. The reluctance of doctors and patients to adopt technologically advanced products because of the significant price gap is likely to slow the market's expansion.
Government Investments for Healthcare Interoperability
The government's increased spending on promoting these solutions is another factor shaping the industry. The growth of the wound care biologics market is aided by factors such as the rising total cost of healthcare, improved healthcare infrastructure, and increasing demand for broader service provision. In addition, numerous institutions dedicated to medical study and patient care are teaming up to improve wound care and create new, effective medications. For instance, scientists are working on ways to incorporate antimicrobial compounds into wound dressings. Furthermore, many research and healthcare institutions are forming collaborations to improve wound care practices and create new, effective drugs. For instance, scientists are working on ways to incorporate antimicrobial compounds into wound dressings.
The global wound care biologics market is segmented by product, wound type, and end-user.
Based on product, the global market is bifurcated into biological skin substitutes and topical agents.
The biological skin substitutes segment is the highest contributor to the market and is expected to grow during the forecast period. These artificial skins are structurally supported by a cellular matrix that has not been damaged. Popular natural skin substitutes include cadaver allografts, amnion, and porcine skin xenografts. Burn victims, those who have been in car accidents, and those who suffer from chronic wounds like diabetic foot or venous leg ulcers are all candidates for biological skin substitutes. Treatments that promote rapid healing of wounds and alleviate symptoms in the elderly are in high demand because of the increasing incidence of these diseases and the size of the elderly population.
Based on wound type, the global wound care biologics market is bifurcated into ulcers, burns, and surgical & traumatic wounds.
The ulcers segment is the highest contributor to the market and is expected to grow during the forecast period. Ulcers are anticipated to be the most lucrative sub-segment of the wound care market because of the increasing use of wound care biologics to treat ulcers and burn injuries. Water loss, heat loss, protein, and electrolyte loss, and contamination are all avoided using biological dressings. Biologics used for wound care have been shown to hasten wound closure and improve the healing environment. Forced quarantine and a shortage of labor and raw materials have severely disrupted the supply of essential materials. Transporting raw materials from one area to another is difficult because of the poor connection between regional warehouses.
Based on end-user, the global market is bifurcated into hospitals, ambulatory surgical centers, and burn centers.
The hospital segment is the highest contributor to the market and is expected to grow during the forecast period. The rising demand for wound care biologics to treat conditions like diabetic foot ulcers, pressure ulcers, and skin burns has contributed significantly to the industry's financial success. In addition, the widespread adoption of allografts and other skin substitutes for managing surgical wounds bodes well for the segment's future expansion. A lower cost structure allows ambulatory surgical centers to offer more affordable procedures than hospitals. The fact that the cost structures are low without sacrificing operational efficiency is a significant factor in their popularity. ASCs are also more likely to be found in outlying areas and rural communities, making them more accessible to patients. It should have a positive effect on the expansion of this market segment.
The global wound care biologics market is bifurcated into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
Regional Growth Insights Request Sample Pages
North America Dominates the Global Market
North America is the most significant shareholder in the global wound care biologics market and is expected to grow during the forecast period. Large numbers of diabetic patients are experiencing rising rates of chronic wounds, which is driving market expansion. The quality of wound care is also improved by the increasing standard of living and disposable income. In addition, the rising incidence of lifestyle-related conditions that cause chronic wounds like diabetic foot ulcers, venous leg ulcers, and pressure ulcers is anticipated to be a driving force in the expansion of the advanced wound care management market in the coming years. More than 29 million Americans have diabetes as of May 2021, and nearly 2 million of them will develop a diabetic foot ulcer or other non-healing wounds each year, per data from Mission Regional Medical Center.
Asia-Pacific is expected to grow during the forecast period. Due to mandatory quarantine and a lack of labor and raw materials, the supply of essential materials has been severely disrupted. Raw materials cannot be transported between regions because of the inefficiency of the link between regional warehouses. The supply chain for wound care biologics in Asia and the Pacific has been impacted by a lack of raw materials and components. Hospitalization is only an option for patients with life-threatening conditions due to a severe lack of medical resources at the front lines. Unfortunately, the virus' pathogenic mechanism has not been fully elucidated, so there is no specific drug and treatment other than symptomatic and supportive care.
Germany is expected to dominate the Europe advanced wound care market with the highest market share because German manufacturers are investing in the country for the dressing segment and diabetes is more prevalent in the country, resulting in a higher number of diabetic ulcers. Growing numbers of older people and a favorable reimbursement environment for wound dressings place the United Kingdom in a position of second-place dominance in Europe's advanced wound care market. Due to an increase in chronic wound cases for the dressing segment in Europe, France is projected to hold the third-largest share of the continent's advanced wound care market.
Increasing healthcare spending in the Middle East and Africa has created an environment where the market for wound care biologics shows enormous growth potential. Rising diabetes rates and the chronic wounds they cause are expected to affect the advanced wound care market, propelling it in the future. The development of the advanced wound care market may be impeded by the high costs associated with wound care treatment. There is a significant opportunity for the advanced wound care market to expand in developing countries due to the introduction of new technologies and products for wound care.
List of top key global wound care biologics market companies profiled
|Market Size||USD in 4.10 Billion By 2031|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Product (Biological Skin Substitutes), Wound Type (Ulcers, Burns, Surgical & Traumatic Wounds), End User|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Smith & Nephew (U.K), Molnlycke health care (Sweden), Integra Lifesciences Corporation (U.S.), Wright Medical (U.S.), MiMedx Group (U.S.), MiMedx Group (U.S.), Kerecis (Iceland), and Anika Therapeutics (U.S.).,|
|Key Market Opportunities||
Government Investments for Healthcare Interoperability